MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'bioMerieux Press Releases' source. Fri, 19 Mar 2010 17:27:58 +0100 http://www.medworm.com/index.php?rid=3342160&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_216 A powerful strategic vision for 2010-2015, driven by innovation and international development. (Source: bioMerieux Press Releases) bioMerieux Press Releases organizations http://www.medworm.com/rss/comments.php?id=3342160 Sun, 07 Mar 2010 23:00:00 +0100 3342160 http://www.medworm.com/index.php?rid=3342159&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_215 Solid operating and financial performance: Strong growth in sales: up 10.4% - At constant exchange rates Significant increase in operating margin: up 14.1%, at 17.4% of sales   The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met on Friday, March 5, 2010 to approve the consolidated financial statements for the year ended December 31, 2009. The meeting was chaired by Alain Mérieux and attended by the Statutory Auditors. The financial statements have been audited and the Statutory Auditors are in the process of issuing an unqualified opinion. (Source: bioMerieux Press Releases) bioMerieux Press Releases organizations http://www.medworm.com/rss/comments.php?id=3342159 Sun, 07 Mar 2010 23:00:00 +0100 3342159 http://www.medworm.com/index.php?rid=3334755&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_214 bioTheranostics, a bioMérieux company that discovers, develops and commercializes innovative molecular diagnostic tests in oncology, announces the launch of an expanded tumor-type database for its flagship product, CancerTYPE ID®, and the launch of KRAS mutational testing. (Source: bioMerieux Press Releases) bioMerieux Press Releases organizations http://www.medworm.com/rss/comments.php?id=3334755 Wed, 03 Mar 2010 23:00:00 +0100 3334755 http://www.medworm.com/index.php?rid=3197267&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_213 bioMérieux, a world leader in the field of in vitro diagnostics, today released its business review for fourth-quarter and full-year 2009. Net sales amounted to €1,223 million in 2009, an increase of 7.7% from the €1,111 million reported in 2008, at constant exchange rates and scope of consolidation (like-for-like). For the fourth quarter alone, net sales amounted to €328 million, compared to €311 million for the prior-year period, up 7.5% like-for-like. (Source: bioMerieux Press Releases) bioMerieux Press Releases organizations http://www.medworm.com/rss/comments.php?id=3197267 Thu, 21 Jan 2010 23:00:00 +0100 3197267 http://www.medworm.com/index.php?rid=3171372&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_212 Company to leverage new production site to capture growth in China and expand Point of Care and rapid diagnostics offer for both emerging and developed countries. A world leader in in vitro diagnostics, bioMérieux announced today the acquisition of the rapid test manufacturer, Meikang Biotech, and its large production site in Shanghai. This important milestone will reinforce bioMérieux’s position in the Point of Care and rapid test markets for both emerging and developed countries. The acquisition highlights bioMérieux’s continued business expansion in fast-growing emerging markets, giving the company fully-owned, integrated manufacturing and R&D capabilities in China. (Source: bioMerieux Press Releases) bioMerieux Press Releases organizations http://www.medworm.com/rss/comments.php?id=3171372 Wed, 13 Jan 2010 23:00:00 +0100 3171372 http://www.medworm.com/index.php?rid=3148694&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_211 Fully automated handheld diagnostic test devices designed to improve diagnosis and disease management in critical care settings within hospitals. Royal Philips Electronics (NYSE: PHG, AEX: PHI) and bioMérieux (NYSE Euronext: BIM) today announced that they have signed an agreement to jointly develop fully automated handheld diagnostic testing solutions for hospital use that can be deployed at the point-of-care – i.e. close to the patient. The collaboration aims to improve diagnosis and management of disease in critical care settings within hospitals (for example, Emergency Departments, Coronary Units and Intensive Care Units (ICUs)). (Source: bioMerieux Press Releases) bioMerieux Press Releases organizations http://www.medworm.com/rss/comments.php?id=3148694 Wed, 06 Jan 2010 23:00:00 +0100 3148694 http://www.medworm.com/index.php?rid=3092341&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_210 - Independent studies validate the utility of THEROS BCI® for risk stratification of early stage breast cancer patients and prediction of response to commonly used aromatase inhibitor – bioTheranostics, a bioMérieux company that develops innovative oncology diagnostic tests to drive personalized treatment, reported today findings from three studies using the company’s breast cancer molecular test. Data from the studies were presented this week at the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS). (Source: bioMerieux Press Releases) bioMerieux Press Releases organizations http://www.medworm.com/rss/comments.php?id=3092341 Fri, 11 Dec 2009 23:00:00 +0100 3092341 http://www.medworm.com/index.php?rid=3074986&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_209 Alain Mérieux confirms the Institute’s commitment to meeting new medical and public health challenges. Mérieux Alliance, the Mérieux family holding company announces today that it changes its name to take on the historic name of Institut Mérieux. At a press conference held in Paris, Alain Mérieux reviewed the important role played by industrial biology in the face of major public health challenges including infectious diseases, cancer, personalized medicine, theranostics and nutrition. Along with Alexandre Mérieux and the management teams, he outlined the many strengths that Institut Mérieux and its companies—bioMérieux, Transgene, ABL and Silliker— will rely upon to meet these challenges in three strategic areas: in vitro diagnostics, immunotherapy, food safety and nutrit... bioMerieux Press Releases organizations http://www.medworm.com/rss/comments.php?id=3074986 Sun, 06 Dec 2009 23:00:00 +0100 3074986 http://www.medworm.com/index.php?rid=3051669&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_208 bioMérieux, a world leader in the field of in vitro diagnostics, today announced that it has sold all of its shares in ExonHit Therapeutics S.A. These shares had been acquired in November 2005, at the initial public offering of ExonHit Therapeutics and their sale is part of bioMérieux's regular stock portfolio management. (Source: bioMerieux Press Releases) bioMerieux Press Releases organizations http://www.medworm.com/rss/comments.php?id=3051669 Wed, 02 Dec 2009 23:00:00 +0100 3051669 http://www.medworm.com/index.php?rid=3051668&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_207 bioMérieux and the CEA (French Atomic Energy Commission) announce today a long-term strategic partnership, intensifying their research collaboration to develop novel technologies for improved infectious disease management. (Source: bioMerieux Press Releases) bioMerieux Press Releases organizations http://www.medworm.com/rss/comments.php?id=3051668 Wed, 02 Dec 2009 23:00:00 +0100 3051668 http://www.medworm.com/index.php?rid=2999137&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_206 bioMérieux has signed an agreement with GlaxoSmithKline to develop a predictive test to help clinicians select the most appropriate treatment for different segments of breast cancer patients. This test, based on emerging biomarkers, will be intended for use in both adjuvant and metastatic breast cancer settings, subject to regulatory approvals. Over 500,000 new cases of breast cancer are diagnosed each year in the US and Europe alone and predictive tests have been shown to improve outcomes for these patients. (Source: bioMerieux Press Releases) bioMerieux Press Releases organizations http://www.medworm.com/rss/comments.php?id=2999137 Mon, 16 Nov 2009 23:00:00 +0100 2999137 http://www.medworm.com/index.php?rid=2984429&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_205 A world leader in the field of in vitro diagnostics, bioMérieux has adapted its molecular NucliSENS EasyQ® Influenza A/B test to include the new A(H1N1) strain. (Source: bioMerieux Press Releases) bioMerieux Press Releases organizations http://www.medworm.com/rss/comments.php?id=2984429 Wed, 11 Nov 2009 23:00:00 +0100 2984429 http://www.medworm.com/index.php?rid=2966713&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_204 Methicillin Resistant Staphylococcus aureus (MRSA) is the most prevalent multi-drug resistant bacteria and a growing threat to health. bioMérieux, a world leader in the field of in vitro diagnostics, today launched NucliSENS EasyQ® MRSA, a new automated test for Methicillin Resistant Staphylococcus aureus (MRSA), one of the leading causes of healthcare-associated infections. NucliSENS EasyQ MRSA is CE marked and bioMérieux will be submitting for 510(k) approval with the U.S. Food and Drug Administration in the first half of 2010. (Source: bioMerieux Press Releases) bioMerieux Press Releases organizations http://www.medworm.com/rss/comments.php?id=2966713 Thu, 05 Nov 2009 23:00:00 +0100 2966713 http://www.medworm.com/index.php?rid=2954046&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_203 A world leader in the field of in vitro diagnostics, bioMérieux has appointed Alain Pluquet to the newly created position of Chief Technology Officer (CTO). (Source: bioMerieux Press Releases) bioMerieux Press Releases organizations http://www.medworm.com/rss/comments.php?id=2954046 Mon, 02 Nov 2009 23:00:00 +0100 2954046 http://www.medworm.com/index.php?rid=2934259&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_202 Chromogenic media provides cost-effective MRSA identification for hospitals and labs. (Source: bioMerieux Press Releases) bioMerieux Press Releases organizations http://www.medworm.com/rss/comments.php?id=2934259 Tue, 27 Oct 2009 23:00:00 +0100 2934259 http://www.medworm.com/index.php?rid=2908190&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_201 2009 Nine-Month Sales up 7.8% at constant exchange rates and scope of consolidation up 11.2% at constant exchange rates, including business development agreements (Source: bioMerieux Press Releases) bioMerieux Press Releases organizations http://www.medworm.com/rss/comments.php?id=2908190 Mon, 19 Oct 2009 22:00:00 +0100 2908190 http://www.medworm.com/index.php?rid=2823602&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_200 Newly evolved enzymes make some bacteria resistant to all common antibiotics Healthcare workers slow to receive flu vaccines Countries not doing enough to combat “superbugs” About 7 million Healthcare-Associated Infections (HAIs) in the U.S. and Europe each year According to a meeting of over 60 infectious disease experts, the global medical community must act on three imminent threats to patients across the world. First threat: common bacteria, such as Escherichia coli (E. coli) are now producing enzymes which make the bacteria capable of de-activating all but the antibiotics that specialists reserve as a last line of defense. Second threat: healthcare workers themselves may be contributing to the spread of infections by failing to get flu vaccinations and, in some countries, coming... bioMerieux Press Releases organizations http://www.medworm.com/rss/comments.php?id=2823602 Tue, 22 Sep 2009 22:00:00 +0100 2823602 http://www.medworm.com/index.php?rid=2772092&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_199 Growth in sales: 10.3 % - At constant exchange rates, including business development agreements 6.0 % - At constant exchange rates and scope of consolidation Growth in operating results before non-recurring items: 16 % (Source: bioMerieux Press Releases) bioMerieux Press Releases organizations http://www.medworm.com/rss/comments.php?id=2772092 Sun, 06 Sep 2009 22:00:00 +0100 2772092 http://www.medworm.com/index.php?rid=2633819&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_198 First-Half 2009 Sales Up 6% at constant exchange rates and scope of consolidation Up 10.3% at constant exchange rates, including business development agreements (Source: bioMerieux Press Releases) bioMerieux Press Releases organizations http://www.medworm.com/rss/comments.php?id=2633819 Thu, 23 Jul 2009 22:00:00 +0100 2633819 http://www.medworm.com/index.php?rid=2587769&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_197 Certification validates high performance test for enhanced food safety. bioMérieux, a world leader in the field of in vitro diagnostics, today announced that an AOAC-RI certification has been granted (No. 060903) to the VIDAS® UP E. coli O157 (Including H7) method for screening beef, selected produce and irrigation water. Food manufacturers in the U.S. and many other countries rely on AOAC-RI certified testing methods to release their products on the market. The new solution is based on recombinant phage protein, the latest technology available for food pathogen screening, which offers unique specificity and sensitivity. E. coli O157:H7 is a potentially lethal strain of Escherichia coli that has caused many food outbreaks in the United States, Canada, Japan, and Europe. (Source: bioMerie... bioMerieux Press Releases organizations http://www.medworm.com/rss/comments.php?id=2587769 Wed, 08 Jul 2009 22:00:00 +0100 2587769 http://www.medworm.com/index.php?rid=2555571&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_196 bioMérieux, a world leader in the field of in vitro diagnostics, today launched VIDAS® EBV for the detection of the Epstein-Barr virus (EBV). This virus causes 80% of cases of infectious mononucleosis, which is often known as “the kissing disease” because it is transmitted through saliva. (Source: bioMerieux Press Releases) bioMerieux Press Releases organizations http://www.medworm.com/rss/comments.php?id=2555571 Mon, 29 Jun 2009 22:00:00 +0100 2555571 http://www.medworm.com/index.php?rid=2504561&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_195 Le Document de référence 2008 de la Société peut être consulté sur le site Internet de l’Autorités des Marchés Financiers (www.amf-france.org) et sur le site Internet de la Société (www.biomerieux.com). (Source: bioMerieux Press Releases) bioMerieux Press Releases organizations http://www.medworm.com/rss/comments.php?id=2504561 Wed, 10 Jun 2009 22:00:00 +0100 2504561 http://www.medworm.com/index.php?rid=2504562&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_194 (Source: bioMerieux Press Releases) bioMerieux Press Releases organizations http://www.medworm.com/rss/comments.php?id=2504562 Tue, 09 Jun 2009 22:00:00 +0100 2504562 http://www.medworm.com/index.php?rid=2468105&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_192 New Molecular Strain Typing Test to Ensure Consistent Quality of Beer.bioMérieux, a world leader in the field of in vitro diagnostics, has launched the DiversiLab® Saccharomyces DNA Fingerprinting kit, which will accurately and reproducibly identify the strain type of yeast used in the brewing of beer. (Source: bioMerieux Press Releases) bioMerieux Press Releases organizations http://www.medworm.com/rss/comments.php?id=2468105 Sun, 07 Jun 2009 22:00:00 +0100 2468105 http://www.medworm.com/index.php?rid=2468106&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_193 - THEROS CancerTYPE ID® predicts cancer origin with 75 percent accuracy in patients whose primary cancer was “unknown” using traditional diagnostics. - bioTheranostics, a bioMérieux company that discovers, develops and commercializes new molecular diagnostic tests in oncology, announced that a recent study demonstrated the company’s THEROS CancerTYPE ID® molecular diagnostic test predicted cancer origin with 75 percent accuracy in patients whose primary cancer was initially “unknown” using traditional diagnostics. Findings were presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, Fl. (Source: bioMerieux Press Releases) bioMerieux Press Releases organizations http://www.medworm.com/rss/comments.php?id=2468106 Sun, 31 May 2009 22:00:00 +0100 2468106 http://www.medworm.com/index.php?rid=2456170&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_191 bioMérieux, a world leader in the field of in vitro diagnostics, presented the latest addition to its HIV testing offer at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). NucliSENS EasyQ® HIV-1 v2.0 is a test able to detect even very low viral load levels in AIDS patients, offering one of the highest degrees of sensitivity available today. (Source: bioMerieux Press Releases) bioMerieux Press Releases organizations http://www.medworm.com/rss/comments.php?id=2456170 Mon, 18 May 2009 22:00:00 +0100 2456170 http://www.medworm.com/index.php?rid=2456171&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_190 bioMérieux, a world leader in the field of in vitro diagnostics, is building upon its Full Microbiology Lab Automation™ (FMLA) concept by offering a new tool to its customers, LeanSigma® - today’s most recognized process and flow improvement methodology. (Source: bioMerieux Press Releases) bioMerieux Press Releases organizations http://www.medworm.com/rss/comments.php?id=2456171 Thu, 14 May 2009 22:00:00 +0100 2456171 http://www.medworm.com/index.php?rid=2456172&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_189 bioMérieux, a world leader in in vitro diagnostics, and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) announce the recipient of their 2009 Research Grant, which recognizes excellence and major contributions to progress in the field of clinical microbiology by a young scientist from Eastern Europe. (Source: bioMerieux Press Releases) bioMerieux Press Releases organizations http://www.medworm.com/rss/comments.php?id=2456172 Mon, 11 May 2009 22:00:00 +0100 2456172 http://www.medworm.com/index.php?rid=2380162&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_188 La Société annonce avoir mis à la disposition du public et déposé auprès de l’Autorité des marchés financiers son rapport financier annuel au 31 décembre 2008. (Source: bioMerieux Press Releases) bioMerieux Press Releases organizations http://www.medworm.com/rss/comments.php?id=2380162 Wed, 29 Apr 2009 22:00:00 +0100 2380162 http://www.medworm.com/index.php?rid=2363849&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_187 Up 6.4% - At constant exchange rates and scope of consolidation. Up 10.6% - At constant exchange rates, including business development agreements. bioMérieux, a global leader in the field of in vitro diagnostics, released its quarterly business review through March 31, 2009. As of March 31, 2009, net sales amounted to €286 million, up 6.4% at constant exchange rates and scope of consolidation (on a like-for-like basis) versus the first quarter of 2008. Factoring in sales related to business development agreements, the increase was 10.6% at constant exchange rates. (Source: bioMerieux Press Releases) bioMerieux Press Releases organizations http://www.medworm.com/rss/comments.php?id=2363849 Wed, 22 Apr 2009 22:00:00 +0100 2363849 http://www.medworm.com/index.php?rid=2326863&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_185 New range will simplify testing for the pharmaceutical industry. bioMérieux, a world leader in the field of in vitro diagnostics and a leading provider of microbiological solutions for the pharmaceutical industry, launches two innovative culture media for Media Fill Tests (MFT): TSB 3PTM with Animal Peptones and TSB 3PTM with Vegetable Peptones and a color indicator to enhance efficiency and reduce potential errors. (Source: bioMerieux Press Releases) bioMerieux Press Releases organizations http://www.medworm.com/rss/comments.php?id=2326863 Mon, 06 Apr 2009 22:00:00 +0100 2326863 http://www.medworm.com/index.php?rid=2273591&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_184 The Board of Directors of bioMérieux, a global leader in the field of in vitro diagnostics, met on Friday, March 13 to approve the consolidated financial statements for the year ended December 31, 2008. The meeting was chaired by Alain Mérieux and attended by the Statutory Auditors. Strong sales growth: +9.8%, at constant exchange rates, including business development Improved operating margin before non recurring-items at 16.8% of sales Substantial R&D and manufacturing investments Three strategic acquisitions and expansion of international network (Source: bioMerieux Press Releases) bioMerieux Press Releases organizations http://www.medworm.com/rss/comments.php?id=2273591 Sun, 15 Mar 2009 23:00:00 +0100 2273591 http://www.medworm.com/index.php?rid=2117485&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_183 bioMérieux, a global leader in the field of in vitro diagnostics, released its business review for fourth-quarter and full-year 2008. 2008 Sales Up 7.5% at constant exchange rates and scope of consolidation (like-for-like) Up 9.8% at constant exchange rates, including business development agreements (Source: bioMerieux Press Releases) bioMerieux Press Releases organizations http://www.medworm.com/rss/comments.php?id=2117485 Mon, 19 Jan 2009 23:00:00 +0100 2117485 http://www.medworm.com/index.php?rid=2105607&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_182 bioMérieux, a world leader in the field of in vitro diagnostics, is enhancing its TEMPO® line for food quality with the launch of one of the most rapid automated solutions for direct enumeration of yeast and mold. TEMPO YM delivers final results in half the time versus most other methods, including the ISO reference method (ISO 21527). (Source: bioMerieux Press Releases) bioMerieux Press Releases organizations http://www.medworm.com/rss/comments.php?id=2105607 Wed, 14 Jan 2009 23:00:00 +0100 2105607 http://www.medworm.com/index.php?rid=2056769&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_180 At the meeting of the bioMérieux Board of Directors held on December 19, 2008, Alexandre Mérieux was appointed as “Directeur Général Délégué” of the Company. Stéphane Bancel continues to be responsible for all functions in his role as Chief Executive Officer and to chair the bioMérieux Management Committee. (Source: bioMerieux Press Releases) bioMerieux Press Releases organizations http://www.medworm.com/rss/comments.php?id=2056769 Sun, 21 Dec 2008 23:00:00 +0100 2056769 http://www.medworm.com/index.php?rid=2056770&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_181 Independent studies validate the utility of Theros BCISM for improving risk stratification of early stage breast cancer patients. (Source: bioMerieux Press Releases) bioMerieux Press Releases organizations http://www.medworm.com/rss/comments.php?id=2056770 Sat, 13 Dec 2008 23:00:00 +0100 2056770 http://www.medworm.com/index.php?rid=2022899&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_179 bioMérieux, a world leader in the field of in vitro diagnostics has acquired PML Microbiologicals Inc., a leading provider of culture media and microbiological products in North America for both clinical and industrial applications. This privately held American in vitro diagnostics company has manufacturing and marketing teams based in Portland, Oregon and Toronto, Canada. (Source: bioMerieux Press Releases) bioMerieux Press Releases organizations http://www.medworm.com/rss/comments.php?id=2022899 Sun, 07 Dec 2008 23:00:00 +0100 2022899 http://www.medworm.com/index.php?rid=2008455&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_178 bioMérieux, a global leader in the field of in vitro diagnostics, today released its business review for the nine months ended September 30, 2008. (Source: bioMerieux Press Releases) bioMerieux Press Releases organizations http://www.medworm.com/rss/comments.php?id=2008455 Mon, 27 Oct 2008 23:00:00 +0100 2008455 http://www.medworm.com/index.php?rid=1912617&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_178 bioMérieux, a global leader in the field of in vitro diagnostics, today released its business review for the nine months ended September 30, 2008. (Source: bioMerieux Press Releases) bioMerieux Press Releases organizations http://www.medworm.com/rss/comments.php?id=1912617 Mon, 27 Oct 2008 23:00:00 +0100 1912617 http://www.medworm.com/index.php?rid=1903628&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_177 bioMérieux, a world leader in the field of in vitro diagnostics, announces the opening of a subsidiary in the United Arab Emirates. A hub for its operations in the Middle East, bioMérieux’s 39th subsidiary will be based in Dubai. (Source: bioMerieux Press Releases) bioMerieux Press Releases organizations http://www.medworm.com/rss/comments.php?id=1903628 Wed, 22 Oct 2008 22:00:00 +0100 1903628 http://www.medworm.com/index.php?rid=1873911&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_176 bioMérieux, a world leader in the field of in vitro diagnostics, is proud to announce that it is the recipient of the Frost & Sullivan 2008 North American Market Leadership Award for Pharmaceutical Microbiology. bioMérieux received an overall score of 10.13 out of a possible 12.00 points, the highest overall Frost & Sullivan Competitive Metrics Score in the U.S. Rapid Pharmaceutical Manufacturing Microbiology Tests Market. The Market Leadership Award is given to a company that displays overall excellence in the market leadership process, including the identification of market challenges, drivers and restraints, brand recognition as well as strategy development and methods of addressing market trends. (Source: bioMerieux Press Releases) bioMerieux Press Releases organizations http://www.medworm.com/rss/comments.php?id=1873911 Mon, 13 Oct 2008 22:00:00 +0100 1873911 http://www.medworm.com/index.php?rid=1827333&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_175 Prostate cancer is the most prevalent cancer in the United States and the 4th most common worldwide. The combination of a test for a new prostate cancer biomarker, Annexin 3, with the standard screening methods could potentially reduce the number of biopsies conducted by up to 75%, when compared with current screening methods alone. (Source: bioMerieux Press Releases) bioMerieux Press Releases organizations http://www.medworm.com/rss/comments.php?id=1827333 Wed, 24 Sep 2008 22:00:00 +0100 1827333 http://www.medworm.com/index.php?rid=1784051&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_174 bioMérieux, a world leader in the field of in vitro diagnostics has acquired the privately held AviaraDx, Inc., a molecular in vitro diagnostics company, based in San Diego, California (USA). AviaraDx’s diagnostic tests, based on their proprietary technologies, are used in the molecular classification of cancers and to assist oncologists in making critical therapeutic decisions. The company has built a molecular R&D lab and a small sales & marketing team, as well as a high complexity Clinical Laboratory Improvement Amendments (CLIA) certified service lab. (Source: bioMerieux Press Releases) bioMerieux Press Releases organizations http://www.medworm.com/rss/comments.php?id=1784051 Wed, 10 Sep 2008 22:00:00 +0100 1784051 http://www.medworm.com/index.php?rid=1784052&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_173 bioMérieux (Euronext: BIM), a global leader in the field of in vitro diagnostics, today released its interim financial report for the first six months of 2008. (Source: bioMerieux Press Releases) bioMerieux Press Releases organizations http://www.medworm.com/rss/comments.php?id=1784052 Sun, 07 Sep 2008 22:00:00 +0100 1784052 http://www.medworm.com/index.php?rid=1784053&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_172 A world leader in the field of in vitro diagnostics, bioMérieux has appointed Steve Harbin as Corporate Vice President, Quality Management Systems, Health, Safety and Environment and Internal Control, effective July 15, 2008. (Source: bioMerieux Press Releases) bioMerieux Press Releases organizations http://www.medworm.com/rss/comments.php?id=1784053 Sun, 31 Aug 2008 22:00:00 +0100 1784053 http://www.medworm.com/index.php?rid=1784054&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_171 bioMérieux, a global leader in the field of in vitro diagnostics, today released its interim review for the six months ended June 30, 2008. (Source: bioMerieux Press Releases) bioMerieux Press Releases organizations http://www.medworm.com/rss/comments.php?id=1784054 Tue, 22 Jul 2008 22:00:00 +0100 1784054 http://www.medworm.com/index.php?rid=1784055&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_170 bioMérieux, a world leader in the field of in vitro diagnostics has concluded an agreement to acquire the privately held AB BIODISK, a Swedish in vitro diagnostics company with facilities for research and development, manufacturing and marketing located in Stockholm. This is bioMérieux’s fourth acquisition in under two years. (Source: bioMerieux Press Releases) bioMerieux Press Releases organizations http://www.medworm.com/rss/comments.php?id=1784055 Tue, 17 Jun 2008 22:00:00 +0100 1784055 http://www.medworm.com/index.php?rid=1784056&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_169 Professor Christian Bréchot has been appointed to the Board of Directors of bioMérieux S.A. during its Annual Shareholder’s Meeting, held on June 12th. (Source: bioMerieux Press Releases) bioMerieux Press Releases organizations http://www.medworm.com/rss/comments.php?id=1784056 Thu, 12 Jun 2008 22:00:00 +0100 1784056 http://www.medworm.com/index.php?rid=1784057&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_168 bioMérieux, a world leader in the field of in vitro diagnostics, is enhancing its line of food safety solutions with the launch of two innovative chromogenic culture media, chromID™ Sakazakii and chromID™ Vibrio. (Source: bioMerieux Press Releases) bioMerieux Press Releases organizations http://www.medworm.com/rss/comments.php?id=1784057 Wed, 11 Jun 2008 22:00:00 +0100 1784057 http://www.medworm.com/index.php?rid=1784058&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_167 bioMérieux, a world leader in the field of in vitro diagnostics, will unveil a new suite of “Full Microbiology Laboratory Automation” solutions at the 108th General Meeting of the American Society for Microbiology (ASM), held June 1-5 in Boston. bioMérieux believes that full microbiology laboratory automation is imperative to streamlining operations and making more reliable results available faster, particularly in light of the growing threat of healthcare-associated infections. Enhanced automation offsets an increasing lack of specialized personnel, contributing to the control of healthcare expenditures. (Source: bioMerieux Press Releases) bioMerieux Press Releases organizations http://www.medworm.com/rss/comments.php?id=1784058 Wed, 28 May 2008 22:00:00 +0100 1784058 http://www.medworm.com/index.php?rid=1784059&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_166 bioMérieux, a leader in the field of in vitro diagnostics and FIND (the Foundation for Innovative New Diagnostics), a Swiss non-profit foundation, have signed a Memorandum of Understanding to jointly undertake development projects in the field of infectious disease diagnostics. (Source: bioMerieux Press Releases) bioMerieux Press Releases organizations http://www.medworm.com/rss/comments.php?id=1784059 Wed, 14 May 2008 22:00:00 +0100 1784059 http://www.medworm.com/index.php?rid=1784060&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_165 Sales up 6.2% like-for-like. (Source: bioMerieux Press Releases) bioMerieux Press Releases organizations http://www.medworm.com/rss/comments.php?id=1784060 Mon, 28 Apr 2008 22:00:00 +0100 1784060 http://www.medworm.com/index.php?rid=1784061&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_163 (Source: bioMerieux Press Releases) bioMerieux Press Releases organizations http://www.medworm.com/rss/comments.php?id=1784061 Mon, 14 Apr 2008 22:00:00 +0100 1784061 http://www.medworm.com/index.php?rid=1784062&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_164 A team of researchers from the University of Sunderland and bioMérieux, a leading company in the field of in vitro diagnostics, have achieved a new step in the fight against Pseudomonas aeruginosa, a bacterium responsible for deadly healthcare-associated infections, which kills tens of thousands of people throughout the world every year .1 (Source: bioMerieux Press Releases) bioMerieux Press Releases organizations http://www.medworm.com/rss/comments.php?id=1784062 Wed, 02 Apr 2008 22:00:00 +0100 1784062 http://www.medworm.com/index.php?rid=1784064&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_162 bioMérieux (Euronext: BIM), a world leader in the field of in vitro diagnostics has entered into a long-term strategic partnership with Hitachi High-Technologies Corporation of Japan. (Source: bioMerieux Press Releases) bioMerieux Press Releases organizations http://www.medworm.com/rss/comments.php?id=1784064 Sun, 16 Mar 2008 23:00:00 +0100 1784064 http://www.medworm.com/index.php?rid=1784063&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_161 2007: Clear improvement in growthand in operating margin before non-recurring items (Source: bioMerieux Press Releases) bioMerieux Press Releases organizations http://www.medworm.com/rss/comments.php?id=1784063 Sun, 16 Mar 2008 23:00:00 +0100 1784063 http://www.medworm.com/index.php?rid=1784065&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_160 bioMérieux (Euronext: BIM), a world leader in the field of in vitro diagnostics, has received 510(k) clearance from the U.S. Food and Drug Administration to market VIDAS® NT-proBNP, a test that helps the diagnosis of heart failure. (Source: bioMerieux Press Releases) bioMerieux Press Releases organizations http://www.medworm.com/rss/comments.php?id=1784065 Wed, 12 Mar 2008 23:00:00 +0100 1784065 http://www.medworm.com/index.php?rid=1784066&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_159 bioMérieux (Euronext: BIM), a world leader in the field of in vitro diagnostics, announces the opening of a subsidiary in Singapore. This 38th subsidiary is another milestone for the company’s international expansion. It will also advance bioMérieux’s Asian development strategy, following recent announcements of joint ventures in China and Japan. (Source: bioMerieux Press Releases) bioMerieux Press Releases organizations http://www.medworm.com/rss/comments.php?id=1784066 Wed, 05 Mar 2008 23:00:00 +0100 1784066 http://www.medworm.com/index.php?rid=1784067&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_158 bioMérieux, a world leader in industrial microbiology control, announces that the first Food Safety Handbook: Microbiological Challenges is now available for food professionals. Published by bioMérieux Editions, the handbook was developed with contributions from 24 internationally renowned experts. (Source: bioMerieux Press Releases) bioMerieux Press Releases organizations http://www.medworm.com/rss/comments.php?id=1784067 Mon, 25 Feb 2008 23:00:00 +0100 1784067 http://www.medworm.com/index.php?rid=1784068&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_157 bioMérieux (Euronext: BIM) and Wescor, an ELITech Group Company have signed an agreement by which bioMérieux will become Wescor’s exclusive worldwide partner for marketing two customized slide stainer instruments for Gram and tuberculosis bacillus under the bioMérieux brand. (Source: bioMerieux Press Releases) bioMerieux Press Releases organizations http://www.medworm.com/rss/comments.php?id=1784068 Wed, 13 Feb 2008 23:00:00 +0100 1784068 http://www.medworm.com/index.php?rid=1784069&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_156 Shanghai Kehua Bio-engineering (Stock Code: 002022) and bioMérieux (Euronext: BIM) announce the creation of a Shanghai-based joint venture to which bioMérieux will transfer microplate immunoassay manufacturing currently located at its Boxtel site in the Netherlands. (Source: bioMerieux Press Releases) bioMerieux Press Releases organizations http://www.medworm.com/rss/comments.php?id=1784069 Wed, 30 Jan 2008 23:00:00 +0100 1784069 http://www.medworm.com/index.php?rid=1784070&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_155 (Source: bioMerieux Press Releases) bioMerieux Press Releases organizations http://www.medworm.com/rss/comments.php?id=1784070 Mon, 21 Jan 2008 23:00:00 +0100 1784070